

OUR SCIENCE 
TAVO SELECT ™ TAVO PRECISE ™ TAVO ELITE ™
OUR PIPELINE 
Disease Focus Pipeline
OUR TEAM 
Management Team Scientific Advisory Board
OUR PARTNERS 
Collaborations Investors
OUR COMPANY
ABOUT US 
News Join Us

info@tavotek.com





BD@tavotek.com Info@tavotek.com



NEWS & Join Us

“The true sign of intelligence is not knowledge but imagination." — Albert Einstein

News

Homepage

Tavotek Pivotal Asset Tavo101&Tavo103 Presented at 2025 AAPS National Biotech Conference

Author:
Origin:
Time of issue:2025-04-27
Views:231

Tavotek Pivotal Asset Tavo101&Tavo103 Presented at 2025 AAPS National Biotech Conference

Author:
Origin:
Time of issue:2025-04-27
Views:231

M1430-02-06-V2.pdf

Previous: Tavotek Pivotal Asset Tavo412 Presented at 2025 AAPS National Biotech Conference

Next: Tavotek Biotherapeutics to Attend 2022 San Antonio Breast Cancer Symposium

Related News

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS

Tavotek Biotherapeutics Doses First Patient in Phase 1 First-in-Human Clinical Trial of TAVO412, a Multispecific Biologic for Solid Tumors

Tavotek Biotherapeutics Named Finalist for 2023 Annual Awards by Life Sciences Pennsylvania

Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment

Tavotek Biotherapeutics Announces Formation and Member of Scientific Advisory Board